Table 3.
Adverse event | DISULF N=53 | NTX N=52 | DISULF+NTX N=49 | PLAC N=54 |
---|---|---|---|---|
Headache | 68% | 63% | 73% | 54% |
Drowsiness | 42% | 40% | 49% | 28% |
Anxiety/irritability | 55% | 46% | 61% | 52% |
Nausea** | 42% | 38% | 57% | 26% |
Upper respiratory tract infection | 45% | 38% | 43% | 50% |
Decreased sexual desire | 32% | 29% | 33% | 28% |
Increased sexual desire* | 11% | 19% | 33% | 28% |
Vomiting | 17% | 23% | 29% | 19% |
Skin rash | 15% | 8% | 10% | 9% |
Difficulty achieving orgasm | 17% | 13% | 14% | 9% |
Toothache | 15% | 21% | 10% | 11% |
Diarrhea | 13% | 8% | 8% | 12% |
DISULF = disulfiram; NTX = naltrexone; PLAC = placebo
p = 0.05;
p = 0.01